Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 4,129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neck Neoplasms Clear all

Conditions: Head Cancer, Neck Cancer
Interventions: Not listed
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Axitinib (AG-013736); Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Oral Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Premalignant Lesion
Interventions: OralViome Cancer Testing System; Device
Lead sponsor: Viome; Industry
Eligibility: 18 Years and older
Enrollment: 475 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Interventions: VV1, Cemiplimab; Biological
Lead sponsor: Vyriad, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 9
States / cities: Santa Monica, California • New Haven, Connecticut • Miami, Florida + 6 more

Conditions: Nasopharyngeal Carcinoma
Interventions: Genetically modified CTLs; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Advanced Solid Tumor Cancer
Interventions: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor; Drug
Lead sponsor: Calico Life Sciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 15
States / cities: Tucson, Arizona • New Haven, Connecticut • Baltimore, Maryland + 11 more

Conditions: Cervical Intraepithelial Neoplasia, Cervical Dysplasia
Interventions: 9-valent HPV vaccine, Imiquimod; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Head and Neck Cancer
Interventions: erlotinib hydrochloride, protein analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, neoadjuvant therapy, therapeutic conventional surgery; Drug · Genetic · Other + 1 more
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Tadalafil, Placebo Pill; Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 99 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cancer
Interventions: ziv-aflibercept; Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: Cervical Cancer, Precancerous Condition
Interventions: folic acid, placebo; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 120 Years · Female only
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pancreatic Cancer, GastroEsophageal Cancer, Rectal Cancer, Head and Neck Cancer, Lymphoma
Interventions: Supportive Oncology Care at Home, Usual Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma, Non-prostate Extrapulmonary Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Thymic Neuroendocrine Carcinoma, Genitourinary Neuroendocrine Carcinoma, Unknown Primary Neuroendocrine Carcinomas, Merkel Cell Carcinoma, Medullary Thyroid Carcinoma
Interventions: 225Ac-ETN029, 111In-ETN029; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 4
States / cities: Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more

Conditions: Recurrent Head and Neck Cancer
Interventions: Ad/PNP, Fludarabine Phosphate; Biological · Drug
Lead sponsor: GeoVax, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Stanford, California • Atlanta, Georgia • Philadelphia, Pennsylvania

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: 0.5 mL Candin®/injection, Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline); Biological · Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 6
States / cities: Fayetteville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 3 more

Conditions: Head and Neck Cancer
Interventions: cisplatin, paclitaxel, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 21 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 215
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more

Conditions: Oropharyngeal Cancer, HPV-Related Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: NavDx; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 45 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2031
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cervical Cancer, Cancer of the Cervix
Interventions: Transvaginal probe using photoacoustic and ultrasound imaging; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Head and Neck Cancer
Interventions: docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization, polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, therapeutic conventional surgery, intensity-modulated radiation therapy, radiation therapy; Drug · Genetic · Other + 2 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Recurrent Head and Neck Carcinoma
Interventions: Brachytherapy, Cesium-131, Conventional surgery; Radiation · Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cervical Cancer, Endometrial Cancer, Vaginal Cancer
Interventions: CT or MRI + Blood Test; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Carcinoma
Interventions: Best Practice, Counseling, Electroencephalography, Neurofeedback, Questionnaire Administration; Other · Procedure · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Squamous Cell Carcinoma
Interventions: Temsirolimus; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma, Uterine Cervical Neoplasms, Carcinoma, Neuroendocrine, Extrapulmonary Small Cell Cancer
Interventions: Topotecan, VX-970 (M6620); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

PET MRI as a Staging Tool for Head and Neck Cancer

Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer

Detection of Oral and Throat Cancers Using OralViome Cancer Testing System

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)

Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery

A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Folic Acid Clinical Trial for the Prevention of Cervical Cancer

Supportive Oncology Care At Home RCT

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer

A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)

Ultrasound and Photoacoustic Imaging for Cervical Cancer

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer

Pelvic Fractures and Radiation Therapy for Cervical Cancer

Interdisciplinary Interventions to Address Pain Management Among Head and Neck Cancer Patients

Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers